STOCK TITAN

Rhythm Pharmaceuticals (RYTM) EPS by Year

RYTM NASDAQ

Rhythm Pharmaceuticals, Inc. lost $3.11 per diluted share in fiscal year 2025. The change from the prior fiscal year is not meaningful, because that figure was zero or negative. Over the trailing 12 months, Q4 FY2025 through Q3 FY2026, the same line adds up to a loss of $2.90 per diluted share. The table below carries 11 fiscal years, from 2015 to 2025, and the quarters Rhythm Pharmaceuticals, Inc. has filed alongside them.

FY2025 annual
EPS (Diluted) -$3.11
YoY n/m
5Y CAGR n/m
Source SEC Filings (10-K/10-Q) Latest period Q3 FY2026, ended Sep 30, 2026 Reported Currency USD

Annual figures, oldest first. Point at a bar to read its period.

RYTM EPS (Diluted) by Fiscal Year

Figures are in USD. Each change compares the year with the year before it, and each column links to the filing it was taken from.

MetricTTMFY2510-KFY2410-KFY2310-KFY2210-KFY2110-KFY2010-KFY1910-KFY1810-KFY1710-KFY1610-KFY1510-K
EPS (Diluted)-$2.90-$3.11n/m-$4.34n/m-$3.20n/m-$3.47n/m-$1.40n/m-$3.04n/m-$3.86n/m-$2.39-$2.83-$2.85n/m-$1.18

TTM is the trailing twelve months, Q4 FY2025 through Q3 FY2026, summed from the four most recent quarterly filings.

RYTM EPS (Diluted) by Quarter

Figures are in USD. Each change compares the quarter with the same quarter a year earlier.

MetricQ3'2610-QQ2'2610-QQ1'2610-QQ4'2510-KQ3'2510-QQ2'2510-QQ1'2510-QQ4'2410-KQ3'2410-QQ2'2410-QQ1'2410-QQ4'2310-K
EPS (Diluted)-$0.61n/m-$0.73n/m-$0.83n/m-$0.73n/m-$0.82n/m-$0.75n/m-$0.81n/m-$0.72n/m-$0.73n/m-$0.55n/m-$2.35n/m-$0.70n/m

What diluted earnings per share means

Diluted earnings per share divides net income by the share count the company would have if every option and convertible security were exercised, which is the more conservative of the two per-share figures a filer reports.

More Rhythm Pharmaceuticals, Inc. financials

Frequently Asked Questions

Rhythm Pharmaceuticals, Inc. lost $3.11 per diluted share in fiscal year 2025.

Rhythm Pharmaceuticals, Inc. (RYTM) reported a loss of $4.34 per diluted share in fiscal year 2024 and a loss of $3.11 per diluted share in fiscal year 2025. A growth rate is not meaningful here, because the earlier figure was zero or negative.

Rhythm Pharmaceuticals, Inc. (RYTM) reported a loss of $2.90 per diluted share over the trailing 12 months, Q4 FY2025 through Q3 FY2026, summed from the four most recent quarterly filings.

Across the 11 fiscal years this page covers, Rhythm Pharmaceuticals, Inc. (RYTM) diluted earnings per share went from -$1.18 in fiscal year 2015 to -$3.11 in fiscal year 2025.

Rhythm Pharmaceuticals, Inc. (RYTM) reported -$0.61 in diluted earnings per share in Q3 2026. The change from the same quarter a year earlier is not meaningful, because that figure was zero or negative.

Diluted earnings per share divides net income by the share count the company would have if every option and convertible security were exercised, which is the more conservative of the two per-share figures a filer reports. This page lists what Rhythm Pharmaceuticals, Inc. (RYTM) reported on that line in every period on record.